Trump's pharmaceutical tariffs could raise costs for patients, worsen drug shortages
1. Trump's pharmaceutical tariffs may disrupt supply chains and raise drug prices. 2. Drugmakers like AbbVie are better positioned due to U.S. manufacturing plants. 3. Tariffs could exacerbate existing drug shortages, impacting affordability for consumers. 4. Branded drugs may see price increases, affecting out-of-pocket costs for patients. 5. Reshoring manufacturing is complex and costly, unlikely to happen quickly.